LCM
IMUX icon

Lynx1 Capital Management’s Immunic IMUX Stock Holding History

Lynx1 Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-107,229
Closed -$3.39M – 15
2022
Q3 		$3.39M Sell
107,229
-3,195
-3% -$134K 3.06% 10
2022
Q2 		$3.83M Buy
+110,424
New +$7.08M 3.26% 8

Other funds holding IMUX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Lynx1 Capital Management's IMUX Position: Q4 2022 in Review

Lynx1 Capital Management sold out of Immunic (IMUX) in Q4 2022, closing a stake of 107,229 shares — an estimated $3.39M sold.

Lynx1 Capital Management first reported a position in IMUX in Q2 2022 and held it in 2 quarters. The position peaked at $3.83M in Q2 2022. 58 funds tracked by Wall St. Rank hold IMUX as of Q4 2022.

  • Lynx1 Capital Management reported no remaining Immunic position as of Q4 2022 after selling out during the quarter.
  • Lynx1 Capital Management sold 107,229 Immunic shares in Q4 2022, an estimated $3.39M.
  • Lynx1 Capital Management first reported a position in Immunic in Q2 2022 and held it in 2 quarters.
  • Lynx1 Capital Management's Immunic position peaked at $3.83M in Q2 2022.
  • 58 funds tracked by Wall St. Rank held Immunic as of Q4 2022.

Based on Lynx1 Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.